Different associations of estrogen receptor beta isoforms, ER beta 1 and ER beta 2, expression levels with tumor size and survival in early- and late-onset breast cancer
No Thumbnail
Authors
Mandušić, VesnaDimitrijević, Bogomir B.
Nikolić-Vukosavljević, Dragica
Nešković-Konstantinović, Zora
Kanjer, Ksenija
Hamann, Ute
Article
Metadata
Show full item recordAbstract
Background: In breast cancer, little is known about the consequences of co-expression of ER alpha with the second estrogen receptor, ER beta, and its isoforms in light of their joint prognostic value. Previously reported correlations have been based mostly on independent ER alpha and ER beta expression levels in breast tumors. Purpose: To address whether the expression ratio of ER alpha and ER beta and its isoforms may be a more important parameter than their absolute levels, we analyzed relative mRNA expression ratios of ER beta 1 to ER beta 2 and ER alpha in 74 clinical samples of invasive breast cancer including 39 early-onset and 35 late-onset breast cancers. Expression levels were correlated with clinical and histopathological parameters and disease-free interval. Results: A specific correlation of ER beta 1 expression levels with tumor size was detected in early-onset breast cancer patients and of ER beta 2 levels with tumor size in late-onset patients. Expression of both ER beta... isoforms inversely correlated with expression of the two estrogen regulated genes, progesterone receptor and pS2 in both groups. Higher levels of ER beta 2 than ER beta 1 isoform were associated with a better outcome in late-onset patients. Conclusions: Our results suggest that different isoforms of ER beta may be involved in suppression of tumor growth in young and elder patients and may have different prognostic values. (C) 2012 Elsevier Ireland Ltd. All rights reserved.
Keywords:
Estrogen receptor beta / Estrogen receptor alpha / Clinical outcome / Early- and late-onset breast cancers / Quantitative RT-PCRSource:
Cancer Letters, 2012, 321, 1, 73-79Funding / projects:
- Molecular determinants for tumor marker design (RS-MESTD-Basic Research (BR or ON)-173049)
- Molecular biomarkers of breast carcinoma and follow-up-dependent changes of thier relevance (RS-MESTD-Basic Research (BR or ON)-175068)
- UICC American Cancer Society Beginning Investigators Fellowship, American Cancer Society [ACS/07/014 2007], Deutsches Krebsforschungszentrum, Heidelberg
DOI: 10.1016/j.canlet.2012.02.022
ISSN: 0304-3835
PubMed: 22366496
WoS: 000307684800009
Scopus: 2-s2.0-84860345854
Collections
Institution/Community
VinčaTY - JOUR AU - Mandušić, Vesna AU - Dimitrijević, Bogomir B. AU - Nikolić-Vukosavljević, Dragica AU - Nešković-Konstantinović, Zora AU - Kanjer, Ksenija AU - Hamann, Ute PY - 2012 UR - https://vinar.vin.bg.ac.rs/handle/123456789/5002 AB - Background: In breast cancer, little is known about the consequences of co-expression of ER alpha with the second estrogen receptor, ER beta, and its isoforms in light of their joint prognostic value. Previously reported correlations have been based mostly on independent ER alpha and ER beta expression levels in breast tumors. Purpose: To address whether the expression ratio of ER alpha and ER beta and its isoforms may be a more important parameter than their absolute levels, we analyzed relative mRNA expression ratios of ER beta 1 to ER beta 2 and ER alpha in 74 clinical samples of invasive breast cancer including 39 early-onset and 35 late-onset breast cancers. Expression levels were correlated with clinical and histopathological parameters and disease-free interval. Results: A specific correlation of ER beta 1 expression levels with tumor size was detected in early-onset breast cancer patients and of ER beta 2 levels with tumor size in late-onset patients. Expression of both ER beta isoforms inversely correlated with expression of the two estrogen regulated genes, progesterone receptor and pS2 in both groups. Higher levels of ER beta 2 than ER beta 1 isoform were associated with a better outcome in late-onset patients. Conclusions: Our results suggest that different isoforms of ER beta may be involved in suppression of tumor growth in young and elder patients and may have different prognostic values. (C) 2012 Elsevier Ireland Ltd. All rights reserved. T2 - Cancer Letters T1 - Different associations of estrogen receptor beta isoforms, ER beta 1 and ER beta 2, expression levels with tumor size and survival in early- and late-onset breast cancer VL - 321 IS - 1 SP - 73 EP - 79 DO - 10.1016/j.canlet.2012.02.022 ER -
@article{ author = "Mandušić, Vesna and Dimitrijević, Bogomir B. and Nikolić-Vukosavljević, Dragica and Nešković-Konstantinović, Zora and Kanjer, Ksenija and Hamann, Ute", year = "2012", abstract = "Background: In breast cancer, little is known about the consequences of co-expression of ER alpha with the second estrogen receptor, ER beta, and its isoforms in light of their joint prognostic value. Previously reported correlations have been based mostly on independent ER alpha and ER beta expression levels in breast tumors. Purpose: To address whether the expression ratio of ER alpha and ER beta and its isoforms may be a more important parameter than their absolute levels, we analyzed relative mRNA expression ratios of ER beta 1 to ER beta 2 and ER alpha in 74 clinical samples of invasive breast cancer including 39 early-onset and 35 late-onset breast cancers. Expression levels were correlated with clinical and histopathological parameters and disease-free interval. Results: A specific correlation of ER beta 1 expression levels with tumor size was detected in early-onset breast cancer patients and of ER beta 2 levels with tumor size in late-onset patients. Expression of both ER beta isoforms inversely correlated with expression of the two estrogen regulated genes, progesterone receptor and pS2 in both groups. Higher levels of ER beta 2 than ER beta 1 isoform were associated with a better outcome in late-onset patients. Conclusions: Our results suggest that different isoforms of ER beta may be involved in suppression of tumor growth in young and elder patients and may have different prognostic values. (C) 2012 Elsevier Ireland Ltd. All rights reserved.", journal = "Cancer Letters", title = "Different associations of estrogen receptor beta isoforms, ER beta 1 and ER beta 2, expression levels with tumor size and survival in early- and late-onset breast cancer", volume = "321", number = "1", pages = "73-79", doi = "10.1016/j.canlet.2012.02.022" }
Mandušić, V., Dimitrijević, B. B., Nikolić-Vukosavljević, D., Nešković-Konstantinović, Z., Kanjer, K.,& Hamann, U.. (2012). Different associations of estrogen receptor beta isoforms, ER beta 1 and ER beta 2, expression levels with tumor size and survival in early- and late-onset breast cancer. in Cancer Letters, 321(1), 73-79. https://doi.org/10.1016/j.canlet.2012.02.022
Mandušić V, Dimitrijević BB, Nikolić-Vukosavljević D, Nešković-Konstantinović Z, Kanjer K, Hamann U. Different associations of estrogen receptor beta isoforms, ER beta 1 and ER beta 2, expression levels with tumor size and survival in early- and late-onset breast cancer. in Cancer Letters. 2012;321(1):73-79. doi:10.1016/j.canlet.2012.02.022 .
Mandušić, Vesna, Dimitrijević, Bogomir B., Nikolić-Vukosavljević, Dragica, Nešković-Konstantinović, Zora, Kanjer, Ksenija, Hamann, Ute, "Different associations of estrogen receptor beta isoforms, ER beta 1 and ER beta 2, expression levels with tumor size and survival in early- and late-onset breast cancer" in Cancer Letters, 321, no. 1 (2012):73-79, https://doi.org/10.1016/j.canlet.2012.02.022 . .